Heron Therapeutics Inc (HRTX) FY2025Q4 Earning Prediction
Heron Therapeutics Inc (HRTX) is set to release its FY2025Q4 earnings performance on 03/09 08:00:00 ET in Pre-Market trading. Consensus forecasts predict a revenue of 39.55M and an earnings per share (EPS) of -0.03 for the FY2025Q4. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Earnings Surprise Analysis
HRTX Transcript
The earnings call highlights strong growth in Acute Care products, particularly ZYNRELEF and APONVIE, with optimistic future guidance and strategic initiatives. Despite some competitive and regulatory challenges, the company exceeded its financial guidance, showing resilience. The Q&A session provided additional positive insights, especially regarding the beneficial impact of the NOPAIN Act and new guidelines for APONVIE. However, some uncertainties remain, such as the litigation outcome and the exact impact timelines. Overall, the strong financial performance and growth potential suggest a positive stock price movement.
The earnings call presents mixed signals: strong revenue growth in key products like ZYNRELEF and APONVIE, but a significant net loss due to debt extinguishment and increased SG&A expenses. The Q&A highlights uncertainties in competitive pressures and future strategies. Positive elements include revised EBITDA guidance and strategic initiatives, but declining margins and unclear management responses temper optimism. With no market cap data, a neutral reaction is expected.
The earnings call indicates strong financial performance with significant year-over-year revenue growth, improved net income, and reduced expenses. Although there are some uncertainties regarding the adoption of ZYNRELEF post-NOPAIN Act, management's strategic refocusing and partnerships seem promising. The positive financial health, coupled with optimistic future guidance, suggests a favorable stock price movement. Despite the lack of immediate impact from the NOPAIN Act, the overall sentiment is positive, driven by strong financial metrics and strategic initiatives.
The earnings call reflects a positive outlook with strong financial performance, improved EBITDA, and net income. Product growth potential and strategic partnerships, like CrossLink, are expected to enhance sales. While there are risks, such as market competition and litigation, the company has managed to mitigate these through settlements. The Q&A section indicates optimism for future sales momentum and profitability, despite management's vague responses on litigation impacts. Overall, the financial health and strategic initiatives suggest a positive stock price movement over the next two weeks.
HRTX Slides
HRTX Report
Frequently Asked Questions
What is the Heron Therapeutics Inc {quarter} Earnings Release Date and Time?
Heron Therapeutics Inc (HRTX) is scheduled to release its {quarter} earnings report on Mar 9, 2026, Pre-Market (approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Heron Therapeutics Inc {quarter} Revenue and EPS?
Analysts' consensus predicts 39.55M in revenue and an EPS of -0.03 for Heron Therapeutics Inc's {quarter}.
What Does Intellectia's AI Predict for Heron Therapeutics Inc {quarter} Earnings?
Intellectia's exclusive AI algorithms forecast a {conclusion} for Heron Therapeutics Inc's {quarter} earnings, with a prediction date of Mar 9, 2026. Heron Therapeutics Inc {summary}
How Can I Use This Earnings Prediction to Trade HRTX Stock?
Leverage Intellectia's AI forecast to position trades ahead of the Mar 9, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Heron Therapeutics Inc {quarter}?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company's earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They're updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
